CStone Pharma Shares Rise on 315% Revenue Surge, Hang Seng Index Inclusion

Shares of CStone Pharmaceuticals (2616.HK) rose more than 4% in early trading on the Hong Kong Stock Exchange, driven by a strong interim earnings report and its pending inclusion in a key market index. The biotech firm's impressive financial performance highlights the significant impact of national insurance coverage on drug sales in China.

Stellar First-Half Earnings

CStone announced in its interim results that total revenue for the first half of the year reached RMB 205 million (approx. $28.3 million), a year-over-year increase of 314.75%. The company stated that drug sales accounted for RMB 183 million of that total.

The revenue was primarily generated by sales of its three core oncology products:

• Gavreto (pralsetinib)
• Ayvakit (avapritinib)
• Sugemalimab

Gavreto Sales Fuel Growth

Ad

The main catalyst for the dramatic revenue increase was the addition of its precision cancer therapy, Gavreto (pralsetinib), to China's National Reimbursement Drug List (NRDL) in January. Inclusion in the NRDL makes innovative drugs significantly more affordable for patients, typically leading to a sharp rise in sales volume.

Following its inclusion, in-hospital sales of Gavreto surged by nearly 500% year-over-year through July, according to the company. This rapid adoption has established the drug as the primary engine of CStone's revenue growth.

Index Inclusion to Broaden Investor Access

Separately, CStone is set to gain wider market exposure after Hang Seng Indexes Company announced the stock's inclusion in the Hang Seng Composite Index. The change will become effective on September 7.

This development is significant as it makes CStone eligible for the southbound Stock Connect program, which allows qualified mainland Chinese investors to trade its shares. Analysts note that inclusion could enhance the stock's trading liquidity and broaden its investor base by tapping into the substantial capital pool in mainland China.